| scholarly article | Q13442814 |
| P50 | author | Margarita Calonge | Q43119624 |
| Ester Carreño | Q43861770 | ||
| Itziar Fernández | Q56440402 | ||
| Carmen García-Vázquez | Q79983690 | ||
| P2093 | author name string | Michael E Stern | |
| Amalia Enríquez-de-Salamanca | |||
| Evangelina Castellanos | |||
| Jose M Herreras | |||
| P2860 | cites work | Comparison of the NEI-VFQ and OSDI questionnaires in patients with Sjögren's syndrome-related dry eye | Q24794134 |
| The biology of VEGF and its receptors | Q27860704 | ||
| The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3 | Q28139712 | ||
| Interleukin-1 receptor antagonist: role in biology | Q28271409 | ||
| A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine | Q28580405 | ||
| Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-alpha and IL-6 by human monocytes | Q31161666 | ||
| A new method for tear film stability analysis using videokeratography | Q33186845 | ||
| Distinctive expression of chemokines and transforming growth factor-beta signaling in human arterial endothelium during atherosclerosis | Q33288811 | ||
| Involvement of the fractalkine pathway in the pathogenesis of childhood hemolytic uremic syndrome | Q33373427 | ||
| Association between high tear epidermal growth factor levels and corneal subepithelial fibrosis in dry eye conditions | Q33845310 | ||
| Tear osmolarity variation in the dry eye. | Q34164990 | ||
| Novel production of interleukin-1 receptor antagonist peptides in normal human cornea | Q34192949 | ||
| Diagnosis of dry eye. | Q34391935 | ||
| Concordance between common dry eye diagnostic tests | Q34412458 | ||
| Grading Of Corneal and Conjunctival Staining in the Context of Other Dry Eye Tests | Q35542950 | ||
| Impact of dry eye syndrome on vision-related quality of life | Q35741609 | ||
| Upregulation of IL-6, IL-8 and CCL2 gene expression after acute inflammation: Correlation to clinical pain | Q36443073 | ||
| Tear osmolarity | Q36471308 | ||
| In vivo confocal microscopy of the ocular surface. | Q36471315 | ||
| Tear cytokine profiles in dysfunctional tear syndrome. | Q36637791 | ||
| Increasing importance of dry eye syndrome and the ideal artificial tear: consensus views from a roundtable discussion | Q36640556 | ||
| Dysfunctional tear syndrome: a Delphi approach to treatment recommendations | Q36653052 | ||
| Optical aberrations and visual disturbances associated with dry eye. | Q36674004 | ||
| IL-17 disrupts corneal barrier following desiccating stress. | Q36676135 | ||
| Anticytokine therapy in neuropathic pain management | Q36998861 | ||
| Interleukin-1 and interleukin-1 antagonism | Q37081535 | ||
| The importance of the precorneal tear film for the quality of optical imaging | Q37295478 | ||
| Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention. | Q37395327 | ||
| Mode of action of cytokines on nociceptive neurons | Q37416067 | ||
| Impression cytology: recent advances and applications in dry eye disease. | Q37453774 | ||
| Cytokine responses by conjunctival epithelial cells: an in vitro model of ocular inflammation | Q39945050 | ||
| Conjunctival cytokine expression in symptomatic moderate dry eye subjects | Q40275692 | ||
| Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. | Q40948258 | ||
| Immunopathogenesis of conjunctival remodelling in vernal keratoconjunctivitis | Q42475067 | ||
| Impaired functional visual acuity of dry eye patients | Q42668504 | ||
| Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease | Q43723395 | ||
| Vascular endothelial growth factor modulates neutrophil transendothelial migration via up-regulation of interleukin-8 in human brain microvascular endothelial cells | Q43850088 | ||
| Classification of chronic blepharitis | Q44080317 | ||
| A comparative study to assess the clinical use of Fluorescein Meniscus Time (FMT) with Tear Break up Time (TBUT) and Schirmer's tests (ST) in the diagnosis of dry eyes | Q44113281 | ||
| The Relationship between Habitual Patient-Reported Symptoms and Clinical Signs among Patients with Dry Eye of Varying Severity | Q44631963 | ||
| The lack of association between signs and symptoms in patients with dry eye disease | Q45122466 | ||
| Correlation between corneal sensitivity, subjective dry eye symptoms and corneal staining in Sjögren's syndrome. | Q45254744 | ||
| Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. | Q45969150 | ||
| Phenol red thread test vs Schirmer's test: a comparative study | Q46636358 | ||
| The height and radius of the tear meniscus and methods for examining these parameters | Q47232848 | ||
| The role of fractalkine as an accelerating factor on the autoimmune exocrinopathy in mice | Q47905844 | ||
| Formation and rupture of the tear film | Q47991713 | ||
| Enhanced generation of helper T type 1 and 2 chemokines in allergen-induced asthma | Q47999349 | ||
| Exposure to a controlled adverse environment impairs the ocular surface of subjects with minimally symptomatic dry eye. | Q50681036 | ||
| Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. | Q51716686 | ||
| Cytokines, matrix metalloproteases, angiogenic and growth factors in tears of normal subjects and vernal keratoconjunctivitis patients. | Q51819157 | ||
| The contribution of lipid layer movement to tear film thinning and breakup. | Q51851737 | ||
| The relative burden of dry eye in patients' lives: comparisons to a U.S. normative sample. | Q51934443 | ||
| Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome. | Q53572321 | ||
| Analysis of inflammatory cytokines in the tears of dry eye patients. | Q54467014 | ||
| Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis. | Q54573513 | ||
| Inflammatory Markers in the Tears of Patients with Ocular Surface Disease | Q58979336 | ||
| Expression of Th-1 Chemokines and Chemokine Receptors on the Ocular Surface of C57BL/6 Mice: Effects of Desiccating Stress | Q61851325 | ||
| Diagnostic tests in patients with symptoms of keratoconjunctivitis sicca | Q69046287 | ||
| Diagnostic tests in the Sicca syndrome | Q70112003 | ||
| Quantitation of tear lysozyme levels in dry-eye disorders | Q71701353 | ||
| Sjögren's syndrome: cytokine and Epstein-Barr viral gene expression within the conjunctival epithelium | Q72120476 | ||
| Human tear film electrolyte concentrations in health and dry-eye disease | Q72388245 | ||
| Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca | Q72993423 | ||
| Expression of IFN-gamma-inducible protein; monocyte chemotactic proteins 1, 3, and 4; and eotaxin in TH1- and TH2-mediated lung diseases | Q73734691 | ||
| Elevated tear interleukin-6 levels in patients with Sjögren syndrome | Q77689430 | ||
| Corneal surface regularity and the effect of artificial tears in aqueous tear deficiency | Q77752013 | ||
| Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells | Q77759136 | ||
| Dry eye: an update on clinical diagnosis, management and promising new treatments | Q78335671 | ||
| Tear film osmolarity: determination of a referent for dry eye diagnosis | Q79143768 | ||
| Association study between the CX3CR1 gene and asthma | Q79326966 | ||
| Development and validation of a short global dry eye symptom index | Q79657699 | ||
| The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007) | Q80347907 | ||
| Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007) | Q80347912 | ||
| Elevated levels of fractalkine expression and accumulation of CD16+ monocytes in glomeruli of active lupus nephritis | Q80526751 | ||
| Increased expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in Wegener's granulomatosis--possible role in vascular inflammation | Q80579654 | ||
| TGF-beta1, IL-1beta, and Th2 cytokines stimulate vascular endothelial growth factor production from conjunctival fibroblasts | Q81552650 | ||
| P921 | main subject | eye disease | Q3041498 |
| P304 | page(s) | 862-873 | |
| P577 | publication date | 2010-05-19 | |
| P1433 | published in | Molecular Vision | Q6895981 |
| P1476 | title | Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease | |
| P478 | volume | 16 |
| Q34912766 | A method to extract cytokines and matrix metalloproteinases from Schirmer strips and analyze using Luminex |
| Q24624909 | A randomized, double-masked study to evaluate the effect of omega-3 fatty acids supplementation in meibomian gland dysfunction |
| Q36523433 | Abnormal activity of corneal cold thermoreceptors underlies the unpleasant sensations in dry eye disease. |
| Q38631332 | Analysis of tear inflammatory mediators: A comparison between the microarray and Luminex methods |
| Q92157905 | Association between the levels of prostaglandin E2 in tears and severity of dry eye |
| Q46073610 | Autoantibodies contribute to the immunopathogenesis of experimental dry eye disease. |
| Q36499692 | Blueberry Component Pterostilbene Protects Corneal Epithelial Cells from Inflammation via Anti-oxidative Pathway |
| Q93039845 | Cathepsin S activation contributes to elevated CX3CL1 (fractalkine) levels in tears of a Sjögren's syndrome murine model |
| Q38633880 | Changes in Tear Cytokine Concentrations Following Discontinuation of Soft Contact Lenses-A Pilot Study. |
| Q33595150 | Changes in cytokines in tears after endoscopic endonasal dacryocystorhinostomy for primary acquired nasolacrimal duct obstruction |
| Q59809188 | Chloroquine Protects Human Corneal Epithelial Cells from Desiccation Stress Induced Inflammation without Altering the Autophagy Flux |
| Q55091063 | Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction. |
| Q89689464 | Comparative lipidomic analysis of inflammatory mediators in the aqueous humor and tear fluid of humans and rabbits |
| Q36300034 | Conjunctival Goblet Cell Function: Effect of Contact Lens Wear and Cytokines |
| Q58122088 | Conjunctival Inflammatory Gene Expression Profiling in Dry Eye Disease: Correlations With HLA-DRA and HLA-DRB1 |
| Q58784904 | Contact-Lens Biosensors |
| Q47250165 | Correlation of interleukin-33 with Th cytokines and clinical severity of dry eye disease |
| Q35178892 | Cytokine changes in tears and relationship to contact lens discomfort |
| Q26746232 | Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease |
| Q37254870 | Differences in Dry Eye Questionnaire Symptoms in Two Different Modalities of Contact Lens Wear: Silicone-Hydrogel in Daily Wear Basis and Overnight Orthokeratology |
| Q37536295 | Discordant Dry Eye Disease (An American Ophthalmological Society Thesis). |
| Q37242107 | Do Cyclosporine A, an IL-1 Receptor Antagonist, Uridine Triphosphate, Rebamipide, and/or Bimatoprost Regulate Human Meibomian Gland Epithelial Cells? |
| Q89928662 | Downregulation of interferon-γ-induced protein 10 in the tears of patients with Stevens-Johnson syndrome with severe ocular complications in the chronic stage |
| Q93109216 | Dry Eye Analysis: A Citation Network Study |
| Q34647761 | Dry eye as a mucosal autoimmune disease |
| Q36799601 | Dry eye disease and microbial keratitis: is there a connection? |
| Q34273384 | Dry eye disease: A review of diagnostic approaches and treatments |
| Q36916372 | Dry eye disease: an immune-mediated ocular surface disorder |
| Q47639135 | Dry eye syndrome: developments and lifitegrast in perspective |
| Q89617981 | Effect of Diquafosol on Hyperosmotic Stress-induced Tumor Necrosis Factor-α and Interleukin-6 Expression in Human Corneal Epithelial Cells |
| Q37485819 | Effect of trapping vascular endothelial growth factor-A in a murine model of dry eye with inflammatory neovascularization |
| Q51836466 | Effects of Aging in Dry Eye. |
| Q36692399 | Effects of L-carnitine, erythritol and betaine on pro-inflammatory markers in primary human corneal epithelial cells exposed to hyperosmotic stress |
| Q36707249 | Effects of Lutein on Hyperosmoticity-Induced Upregulation of IL-6 in Cultured Corneal Epithelial Cells and Its Relevant Signal Pathways. |
| Q36613855 | Effects of a nutraceutical formulation based on the combination of antioxidants and ω-3 essential fatty acids in the expression of inflammation and immune response mediators in tears from patients with dry eye disorders. |
| Q40277929 | Effects of chondrocyte-derived extracellular matrix in a dry eye mouse model |
| Q37692232 | Effects of silk fibroin in murine dry eye. |
| Q55112422 | Efficacy of intra-meibomian gland injection of the anti-VEGF agent bevacizumab for the treatment of meibomian gland dysfunction with lid-margin vascularity. |
| Q35754989 | Efficiency and safety of subconjunctival injection of anti-VEGF agent - bevacizumab - in treating dry eye |
| Q47137945 | Elevation of autophagy markers in Sjögren syndrome dry eye. |
| Q90479096 | Evaluation of a rat meibomian gland dysfunction model induced by closure of meibomian gland orifices |
| Q92237912 | Histamine-Induced Conjunctivitis and Breakdown of Blood-Tear Barrier in Dogs: A Model for Ocular Pharmacology and Therapeutics |
| Q36161620 | Human tear analysis with miniaturized multiplex cytokine assay on "wall-less" 96-well plate |
| Q63315308 | Hyaluronan receptors in the human ocular surface: a descriptive and comparative study of RHAMM and CD44 in tissues, cell lines and freshly collected samples |
| Q26740643 | Immunomodulation on the ocular surface: a review |
| Q82717721 | Inflammatory cytokine profiles in the tears of thyroid-associated ophthalmopathy |
| Q91706370 | Intense Pulsed Light Therapy In The Treatment Of Meibomian Gland Dysfunction: Current Perspectives |
| Q41015875 | Intense pulsed light for evaporative dry eye disease |
| Q37662097 | Interferon-gamma deficiency protects against aging-related goblet cell loss. |
| Q35001933 | Interferon-γ-secreting NK cells promote induction of dry eye disease |
| Q37177382 | Interleukin-1β and tumour necrosis factor-α levels in conjunctiva of diabetic patients with symptomatic moderate dry eye: case-control study |
| Q40043362 | Investigating the Association between Angiogenic Cytokines and Corneal Neovascularization in Sulfur Mustard Intoxicated Subjects 26 Years after Exposure. |
| Q90609961 | Involvement of adiponectin in age-related increases in tear production in mice |
| Q37591609 | Lifitegrast: A novel drug for treatment of dry eye disease |
| Q47437122 | Loss of β Epithelial Sodium Channel Function in Meibomian Glands Produces Pseudohypoaldosteronism 1-Like Ocular Disease in Mice |
| Q41862908 | Lower Vitamin D Level and Distinct Tear Cytokine Profile Were Observed in Patients with Mild Dry Eye Signs but Exaggerated Symptoms |
| Q34028408 | Managing Sjögren's Syndrome and non-Sjögren Syndrome dry eye with anti-inflammatory therapy. |
| Q64273625 | Meibum Expressibility Improvement as a Therapeutic Target of Intense Pulsed Light Treatment in Meibomian Gland Dysfunction and Its Association with Tear Inflammatory Cytokines |
| Q38930001 | Membrane array and multiplex bead analysis of tear cytokines in systemic sclerosis. |
| Q47739620 | Neuropathic pain and dry eye. |
| Q40062999 | Neuropathic symptoms of the ocular surface: dryness, pain, and itch |
| Q33774520 | New testing options for diagnosing and grading dry eye disease |
| Q42777937 | No consequences of dietary n-3 polyunsaturated fatty acid deficiency on the severity of scopolamine-induced dry eye. |
| Q39365232 | Non-invasive objective and contemporary methods for measuring ocular surface inflammation in soft contact lens wearers - A review. |
| Q90182793 | Ocular Manifestations of Rheumatoid Arthritis: Implications of Recent Clinical Trials |
| Q42179004 | Ocular Surface and Tear Film Changes in Older Women Working with Computers |
| Q36475542 | Ocular neuropathic pain |
| Q37427522 | Ocular side effects of biological agents in oncology: what should the clinician be aware of? |
| Q35907009 | Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease |
| Q50991094 | Osmoprotective effects of supplemental epidermal growth factor in an ex vivo multilayered human conjunctival model under hyperosmotic stress. |
| Q37708674 | Oxidative stress and its downstream signaling in aging eyes. |
| Q36957699 | Patients undergoing long-term treatment with antihypertensive eye drops responded positively with respect to their ocular surface disorder to oral supplementation with antioxidants and essential fatty acids. |
| Q27002082 | Practical issues concerning tear protein assays in dry eye |
| Q39030112 | Presence or absence of ocular surface inflammation directs clinical and therapeutic management of dry eye. |
| Q28081311 | Progress in corneal wound healing |
| Q55618002 | RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model. |
| Q61811294 | Review of Biomarkers in Ocular Matrices: Challenges and Opportunities |
| Q41990297 | Role of NFAT5 in inflammatory disorders associated with osmotic stress |
| Q90403125 | Role of tear film biomarkers in the diagnosis and management of dry eye disease |
| Q36338274 | Serum Th1 and Th17 related cytokines and autoantibodies in patients with Posner-Schlossman syndrome |
| Q34325595 | Short-term effects of topical cyclosporine A 0.05% (Restasis) in long-standing prosthetic eye wearers: a pilot study |
| Q89349313 | Suppression of Th1-Mediated Keratoconjunctivitis Sicca by Lifitegrast |
| Q34770248 | Surfactant protein D contributes to ocular defense against Pseudomonas aeruginosa in a murine model of dry eye disease. |
| Q37374838 | T helper cytokines in dry eye disease |
| Q38652990 | TFOS DEWS II Tear Film Report. |
| Q28393435 | Tear cytokine profile as a noninvasive biomarker of inflammation for ocular surface diseases: standard operating procedures |
| Q36980957 | Tear cytokine response to multipurpose solutions for contact lenses |
| Q35570793 | Tear dysfunction and the cornea: LXVIII Edward Jackson Memorial Lecture |
| Q26740411 | Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine |
| Q38975235 | Tear fluid signs associated with filtration blebs, as demonstrated by three-dimensional anterior segment optical coherence tomography |
| Q33756582 | The Growing Need for Validated Biomarkers and Endpoints for Dry Eye Clinical Research |
| Q47884949 | The Pathophysiology of Dry Eye Disease: What We Know and Future Directions for Research |
| Q47639063 | The Relationship Between Ocular Itch, Ocular Pain, and Dry Eye Symptoms (An American Ophthalmological Society Thesis). |
| Q34510429 | The core mechanism of dry eye disease is inflammation |
| Q52768652 | The emerging role of interleukin (IL)-1 in the pathogenesis and treatment of inflammatory and degenerative eye diseases. |
| Q38270449 | The role and treatment of inflammation in dry eye disease |
| Q88390839 | Tolerability of Topical Tocilizumab Eyedrops in Dogs: A Pilot Study |
| Q56363589 | Trehalose/hyaluronate eyedrop effects on ocular surface inflammatory markers and mucin expression in dry eye patients |
Search more.